Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

Based on 1081 first isolates · ED · Cystitis (lower UTI) · 2024-10-27 → 2025-10-26
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 85 % (82 %–87 %)
No tissue or blood levels: cystitis only.
Not covered: Pseudomonas aeruginosa (6 %), Proteus mirabilis (6 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
85 %
79 %
n = 82
meropenem MEM
trend · Escherichia coli reserve
84 %
88 %
n = 82
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
81 %
87 %
n = 82
ciprofloxacin CIP
trend · Escherichia coli
78 %
82 %
n = 82
mecillinam MEC
trend · Escherichia coli lower UTI only
77 %
78 %
n = 82
ceftriaxone CRO
trend · Escherichia coli
75 %
79 %
n = 82
trimethoprim TMP
trend · Escherichia coli lower UTI only
73 %
72 %
n = 82
72 %
78 %
n = 82
54 %
52 %
n = 82
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
7 %
n = 82
6 %
6 %
n = 82
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
1 %
n = 82

Most likely organisms for this profile

Escherichia coli
57 %
Enterococcus faecalis
10 %
Klebsiella pneumoniae
10 %
Pseudomonas aeruginosa
6 %
Proteus mirabilis
6 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.